Skip to main content

Liquidia Corp

corporate_fare Company Profile

Liquidia Corp

LQDA·NASDAQ·Life Sciences·CIK 0001819576

Liquidia Corporation is a biopharmaceutical company focused on respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company operates through its wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia generates revenue from the sale of YUTREPIA (treprostinil) inhalation powder. Additionally, under a promotion agreement with Sandoz Inc. dated August 1, 2018, Liquidia shares profit from the sale of Sandoz's generic treprostinil injection (Treprostinil Injection) in the United States. YUTREPIA is an inhaled dry powder formulation of treprostinil, developed using Liquidia's proprietary PRINT technology. This technology aims to improve treprostinil's therapeutic profile through enhanced deep lung delivery, a low-effort dry-powder inhaler, and the ability to achieve higher dose levels than other marketed inhaled treprostinil therapies. YUTREPIA was approved by the U.S. Food and Drug Administration (FDA) in May 2025 for treating PAH and PH-ILD, with commercialization beginning in June 2025. Liquidia has exclusive rights to commercial activities for Treprostinil Injection in the United States and collaborates with Sandoz on its commercial strategy. Sandoz holds the Abbreviated New Drug Application (ANDA) for Treprostinil Injection and retains all other rights to the product. The company also conducts research, development, and manufacturing of new products. An example is L606, an investigational liposomal formulation of treprostinil, licensed from Pharmosa Biopharm Inc. Liquidia employs a commercial field force targeting healthcare providers and stakeholders involved in treating PAH and PH-ILD in the United States.

Liquidia Corp (NASDAQ:LQDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for LQDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for LQDA spans 8-K, 10-Q, 4, 144.

Recent high-impact activity:

  • Liquidia Q3: YUTREPIA Sales $222.7M, Adjusted EBITDA $140.5M, October Shipments at Record
  • Liquidia Q3: YUTREPIA Sales Hit $222.7M, $389.7M UTC Settlement Charge Drives $236.3M Net Loss
  • Liquidia Posts $2.64 Loss Per Share for Third Quarter
  • Liquidia Settles All UTC Litigation for $380.7M, Preserves YUTREPIA PAH Franchise
  • Liquidia Settles All Litigation With United Therapeutics for $380.7M, Securing YUTREPIA's Future

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$158.32M
Net Income
-$68.92M
Diluted EPS
-$0.80
Op. Cash Flow
-$35.69M
Free Cash Flow
-$40.02M
Operating Income
-$51.38M
Cash & Equivalents
$190.68M
Debt / Equity
0.00×
Net Margin
-43.5%
Shares Outstanding
87.2M sh
Source: 10-K · filed 2026-03-05 · accession 0001104659-26-023804

Short Interest & Short Volume

5.29 days to cover

FINRA reported short interest of 17,511,349 shares in LQDA as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 5.3 days to cover at its recent average daily volume. On November 20, 2026, 43.6% of LQDA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,511,349 shares as of October 30, 2026
Change vs prior period▲ 1.2%
Days to cover5.29 at avg daily volume of 3,312,857
Daily short volume (FINRA facilities)43.6% of 535,790 shares on November 20, 2026
5-day average short volume46.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$54.75 +0.59% today
52-week range · as of 2026-11-10 $22.31 – $93.61
Market cap
$4.9B
Volume
1.7M (0.5× avg)
3-mo avg 3.8M
Live data · 2026-11-22 06:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LQDA - Latest Insights

LQDA
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.45
Real-time Price: $54.75 info
Change: +$7.30 (+15%) info
Market Cap: $4.904B info
LQDA
Nov 10, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.40
Real-time Price: $54.75 info
Change: +$7.35 (+16%) info
Market Cap: $4.904B info
LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $54.75 info
Change: +$4.75 (+10%) info
Market Cap: $4.904B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Updated Oct 14, 7:14 AM ET — Liquidia shares rose 46.10% to $39.17 in overnight trading after the settlement.
Price at Filing: $39.50
Real-time Price: $54.75 info
Change: +$15.25 (+39%) info
Market Cap: $4.904B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Updated Oct 14, 1:08 AM ET — Liquidia shares jumped 42% after the settlement; it will pay $60.3M this month to antitrust parties and reported preliminary Q3 YUTREPIA sa…
Price at Filing: $31.76
Real-time Price: $54.75 info
Change: +$22.99 (+72%) info
Market Cap: $4.904B info
LQDA
Oct 02, 2026, 11:47 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $27.77
Real-time Price: $54.75 info
Change: +$26.98 (+97%) info
Market Cap: $4.904B info
LQDA
Oct 01, 2026, 12:03 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $26.22
Real-time Price: $54.75 info
Change: +$28.53 (+109%) info
Market Cap: $4.904B info
LQDA
Sep 30, 2026, 1:20 PM EDT
Source: Wiseek News
Importance Score:
9
Updated Sep 30, 5:30 PM ET — On September 30, 2026, the court ruled that claims 1 and 14 of the '327 patent are valid and infringed by Liquidia, while the remaining ass…
Price at Filing: $53.22
Real-time Price: $54.75 info
Change: +$1.53 (+3%) info
Market Cap: $4.904B info
LQDA
Sep 30, 2026, 11:42 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $53.22
Real-time Price: $54.75 info
Change: +$1.53 (+3%) info
Market Cap: $4.904B info
LQDA
Sep 03, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.20
Real-time Price: $54.75 info
Change: -$15.45 (-22%) info
Market Cap: $4.904B info
LQDA
Sep 03, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $72.17
Real-time Price: $54.75 info
Change: -$17.42 (-24%) info
Market Cap: $4.904B info
LQDA
Aug 12, 2026, 6:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $54.75 info
Change: -$32.25 (-37%) info
Market Cap: $4.904B info
LQDA
Aug 12, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $54.75 info
Change: -$32.25 (-37%) info
Market Cap: $4.904B info
LQDA
Aug 12, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $90.39
Real-time Price: $54.75 info
Change: -$35.64 (-39%) info
Market Cap: $4.904B info
LQDA
Jul 24, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $86.22
Real-time Price: $54.75 info
Change: -$31.47 (-36%) info
Market Cap: $4.904B info
LQDA
Jun 12, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $71.23
Real-time Price: $54.75 info
Change: -$16.48 (-23%) info
Market Cap: $4.904B info
LQDA
Jun 10, 2026, 4:52 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $65.31
Real-time Price: $54.75 info
Change: -$10.56 (-16%) info
Market Cap: $4.904B info
LQDA
Jun 08, 2026, 4:41 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $64.69
Real-time Price: $54.75 info
Change: -$9.94 (-15%) info
Market Cap: $4.904B info
LQDA
Jun 08, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $64.69
Real-time Price: $54.75 info
Change: -$9.94 (-15%) info
Market Cap: $4.904B info
LQDA
Jun 08, 2026, 4:11 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $63.90
Real-time Price: $54.75 info
Change: -$9.15 (-14%) info
Market Cap: $4.904B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets